- Home
- SNTI vs LPSN Comparison
SNTI vs LPSN Comparison
Compare SNTI & LPSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- LPSN
- Stock Information
- Founded
- SNTI 2016
- LPSN 1995
- Country
- SNTI United States
- LPSN United States
- Employees
- SNTI N/A
- LPSN N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- LPSN EDP Services
- Sector
- SNTI Health Care
- LPSN Technology
- Exchange
- SNTI Nasdaq
- LPSN Nasdaq
- Market Cap
- SNTI 85.3M
- LPSN 71.2M
- IPO Year
- SNTI N/A
- LPSN 2000
- Fundamental
- Price
- SNTI $3.35
- LPSN $0.85
- Analyst Decision
- SNTI Strong Buy
- LPSN Hold
- Analyst Count
- SNTI 1
- LPSN 4
- Target Price
- SNTI $12.00
- LPSN $0.97
- AVG Volume (30 Days)
- SNTI 226.4K
- LPSN 771.5K
- Earning Date
- SNTI 05-06-2025
- LPSN 05-07-2025
- Dividend Yield
- SNTI N/A
- LPSN N/A
- EPS Growth
- SNTI N/A
- LPSN N/A
- EPS
- SNTI N/A
- LPSN N/A
- Revenue
- SNTI N/A
- LPSN $292,025,000.00
- Revenue This Year
- SNTI N/A
- LPSN N/A
- Revenue Next Year
- SNTI N/A
- LPSN $2.35
- P/E Ratio
- SNTI N/A
- LPSN N/A
- Revenue Growth
- SNTI N/A
- LPSN N/A
- 52 Week Low
- SNTI $1.52
- LPSN $0.52
- 52 Week High
- SNTI $16.94
- LPSN $2.08
- Technical
- Relative Strength Index (RSI)
- SNTI 45.79
- LPSN 51.74
- Support Level
- SNTI $3.10
- LPSN $0.77
- Resistance Level
- SNTI $3.50
- LPSN $0.99
- Average True Range (ATR)
- SNTI 0.39
- LPSN 0.06
- MACD
- SNTI -0.07
- LPSN 0.01
- Stochastic Oscillator
- SNTI 20.36
- LPSN 50.04
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About LPSN LivePerson Inc.
LivePerson Inc is the enterprise leader in digital customer conversation. The Conversational Cloud, the Company's enterprise-class digital customer conversation platform, is trusted by the world's top brands to accelerate their contact center transformation, orchestrate conversations across all channels, departments, and systems, increase agent productivity, and deliver more personalized, AI-empowered customer experiences. The company has a presence in the United Kingdom, Asia-Pacific, Latin America, and Europe.